At present, endometriosis remains a worldwide health burden, with the main symptoms of dysmenorrhea, chronic pelvic pain, and infertility, markedly reducing the quality of life (de Ziegler et al., 2010). Although there is no proof that the disease is associated with high mortality, this disorder can significantly contribute to the deterioration of women's general well-being (McPeak et al., 2018). The main current treatment for endometriosis is surgery to remove endometriotic lesions; however, the recurrence rate following surgical treatment is as high as 21.5% at two years and 40.0%‍-‍50.0% at five years post-surgery (Koga et al., 2015). To prevent recurrence, adjuvant treatment with drugs after surgery is recommended to prolong relapse-free intervals. However, it is inconvenient for patients to continuously use such medications in terms of adverse effects and cost (Turk, 2002).
Endometriosis/pathology* ; Endometrium/pathology* ; Female ; Humans ; Ki-67 Antigen/metabolism* ; Quality of Life ; Recurrence ; Telomerase/metabolism* ; Up-Regulation

The cause of perimenopausal depression is not clear, decrease in ovarian function and increase in hormonal fluctuations are considered to be the main causes. With the aging of the population, the incidence of perimenopausal depression increased significantly, which seriously impacts the physical and mental health of women. Screening of depression in perimenopausal women should be conducted to recognize depression in the early stage. In 2018, the North American Menopause Society (NAMS) and the National Network of Depression Centers Women and Mood Disorders Task Group (NNDC) have developed the guideline for the assessment and treatment of perimenopausal depression, which defined the diagnostic criteria for perimenopausal depression. Antidepressants is considered as first-line treatment for perimenopausal depression. However, studies have confirmed that estrogen has antidepressant effects, but there are still different opinions on the application of hormone therapy. This article reviewed this guideline and the latest literatures of the screening, diagnosis and treatment of perimenopausal depression.

The cause of perimenopausal depression is not clear, decrease in ovarian function and increase in hormonal fluctuations are considered to be the main causes. With the aging of the population, the incidence of perimenopausal depression increased significantly, which seriously impacts the physical and mental health of women. Screening of depression in perimenopausal women should be conducted to recognize depression in the early stage. In 2018, the North American Menopause Society (NAMS) and the National Network of Depression Centers Women and Mood Disorders Task Group (NNDC) have developed the guideline for the assessment and treatment of perimenopausal depression, which defined the diagnostic criteria for perimenopausal depression. Antidepressants is considered as first-line treatment for perimenopausal depression. However, studies have confirmed that estrogen has antidepressant effects, but there are still different opinions on the application of hormone therapy. This article reviewed this guideline and the latest literatures of the screening, diagnosis and treatment of perimenopausal depression.

NADPH oxidases are a family of multi-subunit enzyme eomplexes.It catalyzes the production of reactive oxygen species (ROS).A large number of studies have shown that oxidative stress plays a very important role in cerebral ischemia-reperfusion injury,and the find of the expression changes about NADPH oxidase after cerebral ischemia may provide a new idea for the prevention and treatment of ischemic stroke.NADPH oxidase may become a new therapeutic target.